Paper Details

  1. Home
  2. Paper Details

Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.

Author: AkazawaManabu, NarimatsuHiroto, SasaharaYuriko, TakumotoYuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study compares various first-line chemotherapy regimens for patients with metastatic pancreatic cancer in Japan, including gemcitabine (GEM), FOLFIRINOX, GEM+NPTX, and S-1. While these regimens have been approved, direct comparisons are limited, necessitating further research to determine the most effective treatment approach.
Paper Details　
Original Abstract of the Article :
Various first-line chemotherapy treatment regimens for patients with metastatic pancreatic cancer have been approved in Japan, including gemcitabine (GEM); fluorouracil, leucovorin, irinotecan, and oxaliplatin combination (FOLFIRINOX); GEM plus albumin-bound paclitaxel (GEM+NPTX), and S-1 (tegafur +...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804927/

データ提供：米国国立医学図書館（NLM）

Navigating the Landscape of Pancreatic Cancer Treatment

Pancreatic cancer is a formidable adversary, often diagnosed at a late stage, making treatment challenging. This systematic review and network meta-analysis delve into the effectiveness of various first-line chemotherapy regimens used in Japan for metastatic pancreatic cancer, providing a valuable comparison of different treatment options.

Comparing Chemotherapy Regimens for Pancreatic Cancer

The study compares the effectiveness of several chemotherapy regimens, including gemcitabine, FOLFIRINOX, GEM plus albumin-bound paclitaxel (GEM+NPTX), and S-1 (tegafur + gimeracil + oteracil), offering valuable insights into their relative strengths and weaknesses. It identifies promising regimens that may offer improved outcomes for patients with metastatic pancreatic cancer.

Guiding Treatment Decisions in Pancreatic Cancer

This comprehensive analysis provides clinicians with valuable information to guide treatment decisions for patients with metastatic pancreatic cancer. It helps to optimize treatment strategies by identifying regimens that may offer superior outcomes and enhance the overall quality of life for patients.

Dr. Camel's Conclusion

Just like a camel trekking across a challenging desert, navigating the complex world of pancreatic cancer treatment requires careful consideration. This study equips clinicians with the necessary tools to make informed treatment decisions, enhancing the chances of successful outcomes for their patients.
Date :
  1. Date Completed 2022-02-22
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

35099549

DOI: Digital Object Identifier

PMC8804927

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.